425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
8-K: Current report
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
8-K: Current report
ARS: Annual Report to Security Holders
DEF 14A: Definitive information statements
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
8-K: Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
10-Q: Quarterly report
S-4: Registration of securities issued in business combination transactions
8-K: Current report
8-K: Current report
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Kintara Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Kintara Therapeutics | 8-K: Current report
Kintara Therapeutics | RW: Registration Withdrawal Request
Kintara Therapeutics | 8-K: Current report
Kintara Therapeutics | 8-K: Current report
Kintara Therapeutics | 8-K: Current report
Kintara Therapeutics | 8-K: Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
No Data